Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database - PubMed (original) (raw)
Clinical Trial
Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database
Hans Christoph-Diener et al. Neurology. 2004.
Abstract
Objective: The efficacy and tolerability profiles of sumatriptan and other 5HT(1B/1D) agonists (triptans) have been well established. However, the determinants for optimal response to sumatriptan are unknown. The Sumatriptan Naratriptan Aggregate Patient (SNAP) database contains data from 128 clinical trials including 28,407 migraine sufferers treating over 130,000 attacks. The authors analyzed these data to identify factors predicting response (headache relief and pain-free response) to sumatriptan.
Methods: The authors assessed 24 possible univariate predictors of headache response in 3,706 patients (18 years and older) receiving sumatriptan tablets 100 mg or placebo in a double-blind study using recursive partitioning and logistic regression techniques.
Results: The authors found seven predictors of headache relief 2 hours postdose. Moderate pain at baseline was the strongest predictor (adjusted p = 3.32 x 10(-35)), followed by absence of a disability requiring bedrest (adjusted p = 3.11 x 10(-18)). Other predictors included absence at baseline of vomiting, pulsating pain, nausea, or photophobia/phonophobia, and onset of headache during daytime hours. Logistic regression confirmed that treatment with sumatriptan was the strongest predictor of headache relief, with significant baseline covariates being pain severity, level of disability, and presence or absence of vomiting. A similar pattern of results was reported for predictors of pain-free response 2 hours after taking sumatriptan.
Conclusions: Pretreatment pain severity is the most important predicting factor for response to sumatriptan in migraine attacks: the lower baseline severity, the better.
Similar articles
- A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Winner P, Ricalde O, Le Force B, Saper J, Margul B. Winner P, et al. Arch Neurol. 1996 Feb;53(2):180-4. doi: 10.1001/archneur.1996.00550020092020. Arch Neurol. 1996. PMID: 8639069 Clinical Trial. - Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
Lipton RB, Pascual J, Goadsby PJ, Massiou H, McCarroll KA, Vandormael K, Jiang K, Lines CR. Lipton RB, et al. Headache. 2001 Sep;41(8):754-63. doi: 10.1046/j.1526-4610.2001.01139.x. Headache. 2001. PMID: 11576198 - Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults.
Derry S, Moore RA, McQuay HJ. Derry S, et al. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008040. doi: 10.1002/14651858.CD008040.pub2. Cochrane Database Syst Rev. 2010. PMID: 21069700 Free PMC article. Updated. Review. - Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
Cady R. Cady R. Headache. 2002 Jan;42 Suppl 1:26-31. doi: 10.1046/j.1526-4610.2002.0420s1026.x. Headache. 2002. PMID: 11966861 - Spotlight on almotriptan in migraine.
Keam SJ, Goa KL, Figgitt DP. Keam SJ, et al. CNS Drugs. 2002;16(7):501-7. doi: 10.2165/00023210-200216070-00006. CNS Drugs. 2002. PMID: 12056924 Review.
Cited by
- The Gut-brain Connection and Episodic Migraine: an Update.
Nguyen L, Hindiyeh N, Ray S, Vann RE, Aurora SK. Nguyen L, et al. Curr Pain Headache Rep. 2023 Nov;27(11):765-774. doi: 10.1007/s11916-023-01175-6. Epub 2023 Oct 4. Curr Pain Headache Rep. 2023. PMID: 37792173 Free PMC article. Review. - Predicting Sumatriptan Responsiveness Based on Structural Connectivity in Patients Newly Diagnosed With Migraine.
Lee DA, Kim HC, Lee HJ, Park KM. Lee DA, et al. J Clin Neurol. 2023 Nov;19(6):573-580. doi: 10.3988/jcn.2022.0479. Epub 2023 Jun 1. J Clin Neurol. 2023. PMID: 37455509 Free PMC article. - Patient Factors in the Dose Selection of Oral Sumatriptan for Acute Migraine: A Post Hoc Analysis of Two Randomized Controlled Studies.
Fisher M, Aher A, Araga M, Franks B. Fisher M, et al. Pain Ther. 2023 Jun;12(3):853-861. doi: 10.1007/s40122-023-00511-3. Epub 2023 Apr 27. Pain Ther. 2023. PMID: 37103731 Free PMC article. - The Use of Neuroimaging for Predicting Sumatriptan Treatment Response in Patients With Migraine.
Wu JW, Lai PY, Chen YL, Wang YF, Lirng JF, Chen ST, Lai KL, Chen WT, Wu YT, Wang SJ. Wu JW, et al. Front Neurol. 2022 Jan 31;13:798695. doi: 10.3389/fneur.2022.798695. eCollection 2022. Front Neurol. 2022. PMID: 35173673 Free PMC article. - Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review.
Leroux E, Buchanan A, Lombard L, Loo LS, Bridge D, Rousseau B, Hopwood N, Matthews BR, Reuter U. Leroux E, et al. Adv Ther. 2020 Dec;37(12):4765-4796. doi: 10.1007/s12325-020-01494-9. Epub 2020 Sep 29. Adv Ther. 2020. PMID: 32990921 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical